"Beyond Reproduction: The Comprehensive Benefits of Estrogen Unveiled”
My Mission is simple: to equip WOMEN with the KNOWLEDGE and EDUCATION they need to confidently navigate the menopausal journey and embrace AGING with GRACE and EMPOWERMENT.
As a Health, Wellness, Mindset, and Menopause Coach, I can help you establish a new lifestyle.
I highly recommend every woman should read this book for their knowledge. The book serves as a valuable resource, empowering women to make informed decisions about their hormonal health and advocating for personalized approaches to hormone replacement therapy that prioritize individual well-being.
Estrogen Matters" by Avrum Bluming, M.D., and Carol Tavris, Ph.D., is a book that challenges misconceptions about estrogen therapy and emphasizes its profound impact on women's well-being. The authors present a nuanced perspective that underscores the hormone's significance in maintaining bone density, cardiovascular health, cognitive function, and emotional balance.
Through a thoughtful synthesis of scientific evidence, the authors affirm the need for a more nuanced and informed dialogue about estrogen, shedding light on its manifold benefits and its integral place in women's health.
“Unraveling the Women's Health Initiative: The Enduring Panic Surrounding Estrogen and Breast Cancer”
Today's blog is extensive as it delves into the vast controversy surrounding Estrogen. During my last few weeks of research, I have discovered that we have been misled regarding Estrogen. I am shocked that a select few could have such a significant impact on women's ability to make informed decisions about their health. As you read this blog, I hope you will understand what happened and continue researching what is best for you. For me, there is no question that Estrogen has made a significant impact on my health, mindset, and overall quality of life.
History of Estrogen:
The use of hormone replacement therapy (HRT) dates back to the 1960s and gained immense popularity in the 1990s. Clinical trials on HRT and chronic postmenopausal conditions were conducted in the USA in the late 1990s. However, the announcement of the first results of the Women's Health Initiative (WHI) in 2002, which showed that HRT had more harmful than beneficial effects, led to a drop in its usage. The study's negative results received widespread publicity, causing panic among some users and new guidance. However, a reanalysis of the WHI trial was conducted in the following years, and recent studies have shown that the use of HRT in younger women or early postmenopausal women has a beneficial effect on the cardiovascular system, reducing coronary disease and all-cause mortality and helping overall symptoms of Menopause. Despite this, public opinion on HRT has not changed yet, leading to critical negative consequences for women's health and quality of life.
The Women's Health Initiative:
The Women's Health Initiative (WHI) was a groundbreaking long-term health study initiated by the U.S. National Institutes of Health (NIH) in 1991. The study addressed critical questions about women's health and aging, covering hormone replacement therapy, dietary patterns, and preventive interventions. Specifically, the WHI sought to provide evidence-based insights into the risks and benefits of various health strategies for women undergoing Menopause. The study involved three major clinical trials, as well as observational research, spanning 15 years. The WHI was a collaborative effort within the scientific and medical community, with numerous scientists, clinicians, and healthcare professionals participating in its planning, execution, and analysis. The WHI played a pivotal role in shaping medical understanding of women's health, influencing clinical practices, and fostering ongoing research endeavors to enhance the well-being of women across their lifespan.
The Two Trials by the WHI That Shaped Estrogen. The Estrogen-Alone Trial and The Estrogen + Progestin.
The Estrogen-alone trial was conducted on 10,739 postmenopausal women who had undergone a hysterectomy and were prescribed estrogen therapy alone. The Estrogen + Progestin Trial involved 16,608 women who had their uterus and were prescribed Estrogen + Progestin. The primary aim of both trials was to evaluate the effects of Estrogen on chronic diseases such as breast cancer, cardiovascular events, and osteoporosis. The clinical trials involved women aged between 50 and 79 years who were in good health at the beginning of the trial. The women were divided into three categories based on their age: 50 to 59 years old (32.3%), 60 to 69 years old (45.2%), and 70 to 79 years old (22.5%). The average age of the women who participated in the trials was 63.6 years. (It is essential to note the age range of the participants in the trials and that they were to be in good health.)
The Panic Unleashed.
The Estrogen + Progestin trial
The first results of the WHI Estrogen + Progestin trial were published in 2002 after a mean follow-up period of 5.2 years. In the group with intact uteri, an increased incidence of coronary heart disease and breast cancer was observed, along with a reduction of osteoporotic fractures and colorectal cancer. Given these results, the risks outweighed the benefits, and the trial was prematurely discontinued. The data was primarily given to the media, creating panic among HRT users and forcing new guidance for doctors on prescribing HRT. The message was that HRT, with no specification of type and route of administration, was associated with more risks than benefits.
The Estrogen-only Trial
The trial with only Estrogen (performed in women with a hysterectomy) continued, and the preliminary data was published in 2004. In addition, this trial was stopped prematurely after 6.8 years of follow-up due to evidence of a small increased risk of ischemic stroke in the absence of other significant cardiovascular benefits. Despite the benefits (such as a reduction of osteoporotic fracture and colon cancer) and of the not-increased risk of breast cancer or cardiovascular disease, the overall message on HRT remained negative. This decision had significant implications for the medical community's understanding of hormone replacement therapy, leading to a reevaluation of its risks and benefits in postmenopausal women and influencing clinical recommendations. However, it was the alarming association with breast cancer that sent shockwaves through the medical community and the general public. The Two incomplete trials set panic in motion that still exists today.
The Problem with the results
The Women's Health Initiative (WHI) study has been a topic of ongoing discussions and controversies since its inception. The study's design and conclusions have been extensively debated, and many of its results have been questioned. One of the critical limitations of the WHI was that most participants were more than ten years past their final menstrual period, which raised concerns about whether the trial results could be applied to younger women. The WHI only tested two formulas, leaving doubts about the safety and effectiveness of other HRT formulations and delivery methods. Despite its limitations, the WHI hurt the global perception of HRT, leading to a marked decline in HRT utilization. Many doctors stopped prescribing HRT, and many women abandoned HRT immediately.
The conflicting findings between the Women's Health Initiative (WHI) and previous observational studies were due to the difference in age of the women enrolled. Some observational studies included symptomatic women who had started Hormone Replacement Therapy (HRT) near the onset of menopause. On the other hand, women enrolled in the WHI trial were asymptomatic, older (with an average age of 63.2), and frequently more than ten years past the start of menopause. Another significant factor is that the women in the WHI trials were not in the best of health, with 35% being overweight, 34% being obese, and 36% having high blood pressure, among other things.
The WHI continued for 13 years, and some results, including an age stratification of the cardiovascular outcomes, were published in the following years. A reanalysis of the WHI trial with new studies and a meta-analysis showed that the use of HRT in younger women (50–59 years) or early postmenopausal women (within ten years of menopausal onset) had a beneficial effect on the cardiovascular system, reducing coronary diseases and all-cause mortality. Furthermore, a large controlled trial from Denmark (reported in 2012) demonstrated that healthy women taking combined HRT for ten years immediately after Menopause had a reduced risk of heart disease and death from heart disease. It has been suggested that a "window of opportunity" may exist, a period close to menopause where the benefits of HRT exceed the risks. Unfortunately, this data did not receive appropriate coverage by the media, and the fear regarding HRT has persisted.
Just a couple of tidbits!
In 2007, five years after the initial study, a writer from Scientific American interviewed several Women's Health Initiative (WHI) Study leaders to get their current views. Joan Manson, one of the leaders, admitted that they should have considered differences in age and time from Menopause more closely, based on all previous research. She added that including this information in the report could have provided a better perspective for younger women.
A 2012 article published in Lancet Oncology reported that the WHI had started to backtrack on its previous claims about the link between estrogen and breast cancer. The article stated that women who were on hormone replacement therapy (HRT) were less likely to die from breast cancer compared to those who were assigned a placebo.
In 2014, Samuel Shapiro, then in the Department of Public Health and Family Medicine at the University of Cape Town medical school, and his colleagues conducted an in-depth statistical analysis of the WHI Study. They concluded that “the over-interpretation and misrepresentation of the finding in the WHI study resulted in significant damage to the health and well-being of menopausal women. (Read Below)
Conclusion
Hormone Replacement Therapy (HRT) has a controversial history due to its side effects and complications. Although it was a potent treatment for postmenopausal symptoms, its use was limited. However, when HRT was combined with progestin, it became widely used and had favorable effects on women's health. Unfortunately, the publication of the inadequately designed, evaluated, and reported WHI trial abruptly stopped the surge in HRT use, leaving many symptomatic women without an effective treatment. Further studies have shown that HRT is highly beneficial when given to symptomatic women within ten years of the onset of menopause or to symptomatic women under 60 years of age. However, low HRT use, which is unjustified, continues to occur worldwide.
Despite having multiple opportunities to acknowledge their mistakes, the Women's Health Initiative (WHI) has yet to make any positive statements about Hormone Replacement Therapy (HRT), especially when their data shows that HRT can be a benefit. Additionally, if HRT was indeed harmful to the health of postmenopausal women, the significant reduction in its use should have resulted in an improvement in women's health. However, the opposite has been observed. Estrogen is an essential hormone in a woman's body that offers many benefits. It is crucial in developing and maintaining the female reproductive system, including regulating the menstrual cycle and supporting healthy bone density. Beyond its reproductive functions, estrogen helps to keep smooth, supple skin and promotes cardiovascular health by influencing cholesterol levels. It is associated with cognitive function, potentially affecting memory and mood regulation. However, it is essential to note that while estrogen provides numerous benefits, its balance in the body is crucial. The absence of estrogen can lead to various health issues, including osteoporosis, cardiovascular disease, and cognitive decline. Therefore, HRT can be a viable option for women experiencing menopausal symptoms, especially when given within ten years of the onset of menopause or to symptomatic women under 60 years of age. It is imperative to consider the benefits and risks of HRT and make an informed decision based on individual health needs.
I have used various studies and references in this blog. It is essential to note that many of these studies relied on data mining to reach their conclusions. This implies that if they did not obtain the desired results, they continued to analyze the data until they found something that supported their claims and presented it as a fact.
I am committed to sharing my knowledge and expertise on managing Menopause, Fitness, Mindset, and Nutrition through my blog. Here, you will find helpful advice and perspectives that I have used and developed to cope with the unique challenges of this phase in life. Through my guidance, I hope you will feel empowered and equipped to tackle the obstacles that come with Menopause.
All opinions are always 100% honest and my own and are based on what I have been through in my 50s with Perimenopause, Menopause, Post-menopause, and Cancer. I am not an expert or claim to be one.
Just a participant in Menopause.
If you visit my resources page, links are affiliate links. I receive a commission for the sale if you click a link and buy something. It doesn't cost you anything extra; you can use the link or not as you choose. If you do use my links, I appreciate your support. These are just a few of my lifestyle habits.
Contact me for more information.
